Clinical Trial Update: Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS [Phase 3]

View source ↗

Summary

Non-inferiority Phase 3 trial comparing rituximab to ocrelizumab in relapsing multiple sclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)
• Rituximab (rituximab)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: RECRUITING